ArticlePituitary2025
An endocrinological point of view on a large series of pituitary stalk lesions.
Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePituitary stalk lesions (PSL) present unresolved etiological and diagnostic challenges. This study provides a comprehensive clinical analysis to address these gaps.
methodsWe retrospectively evaluated 98 adults with pituitary stalk (PS) abnormalities, assessing PS features, demographics, clinical data, hormonal profiles, imaging, pathology, diagnoses, and treatments.
resultsAmong 98 patients (59 F/39 M; median age 37 years), PS thickening was most frequent (52%), followed by thinning (18.4%) and nodularity (17.3%). The distribution of lesion types varied significantly across etiological categories (p < 0.001). Thickening was most frequent in inflammatory etiologies, thinning in unclassifiable cases, and nodularity in inflammatory etiologies. Solid organ metastases occurred in older patients. Arginine vasopressin deficiency (AVP-D) rates ranged from 57% to 61% in non-adenomatous local neoplastic lesions, inflammatory etiologies, and solid organ metastases. Congenital cases mainly had growth retardation and gonadal dysfunction. Extrapituitary involvement was highest in solid organ metastases, followed by inflammatory etiologies, and non-adenoma local neoplastic lesions. PS thickening was more pronounced in solid organ metastases. Isolated PS involvement was most often (25%) due to Langerhans cell histiocytosis. In PSIS, all had ectopic neurohypophysis, lacked AVP-D, and showed at least one anterior pituitary hormone deficiency.
conclusionIn conclusion, we describe a unique series of PSL that contribute to the understanding of the heterogeneous spectrum of PSL. In this study, we discuss the clinical and radiological features of PSL and provide current recommendations for differential diagnosis.
Indexed as
Identifiers
41364245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.